“um when, I'm sorry, December of 2022, when, sorry, December of 2021, when that deal was negotiated. And since then, ah the markets had, you know, went through the last couple of years of pain. And hopefully now with ah kind of the macro conditions changing and inflation coming down, maybe interest rates coming down, ah you know, very soon, things can change. But it did get us through this period of time that has been very challenging for biotech companies for smaller pre-revenue early stage biopharma companies.”